Home / Knowledge Centre /

Optimising Assays from FFPE for Biomarker Strategies

The field of personalized medicine is developing rapidly and companion diagnostic approvals are becoming more and more common. To date, however, the vast majority of tests are relatively low complexity DNA or protein based assays. In our experience, more complex gene signature based tests are beginning to enter the pipeline with many of our clients currently using these tests for trial enrichment strategies as early as Phase I.

When it comes to clinical delivery of such assays, the ability to work with FFPE tissue is critically important. This is an area of significant experience and expertise for Almac and in this webinar we will present some of our experience.

Some of the key components will be:

  • Platforms, platform selection and migration
  • Optimizing tests for FFPE tissue
  • Clinical delivery for trial enrichment
  • Development routes for companion diagnostics

Speaker for this Event: Dr. Austin Tanney, Scientific Liaison Manager, Almac

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Please complete this form to view the Webinar

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies